Impact ledger

Gossamer Bio, Inc. (GOSS): the developments shaping its investment case

Follow the evidence affecting Gossamer Bio, Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research Gossamer Bio, Inc. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-09

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Channel: A reverse stock split, while technically neutral to market capitalization, is often perceived negatively by investors as it frequently indicates a company's struggle to maintain its stock price above exchange minimums. This can lead to reduced investor confidence, increased short-selling interest, a

Bearish· 1-3m

2026-08-21

Gossamer Bio, Inc. Follow-On — $250M

Channel: Direct equity dilution, increased cash runway, reduced near-term bankruptcy risk, potential for increased R&D spend, and market perception of financing terms.

mixed· 1-3m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-08-21	multiple	Bearish	Incremental float typically compresses near-term multiple absent revenue acceleration.
2026-08-21	share_count	Bullish	Primary equity issuance increases diluted share count.
2026-07-01	interest_expense	Bullish	Coupon adds to interest expense until conversion.
2026-07-01	dilution	Bullish	Convertible issuance creates contingent dilution at conversion price.
2026-06-17	share_count	Bullish	Stock component of consideration dilutes existing acquirer holders.
2026-06-17	net_debt	Bullish	Cash component of consideration is typically debt-funded, raising net debt.
2026-06-17	revenue	Bullish	Acquisition adds target revenue to acquirer P&L on close.
2026-06-17	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-06-17	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.

Event impact log

2 events mapped to GOSS since 2026-08-21. Evidence through 2026-09-09.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-09	Gossamer Bio Announces 1-for-80 Reverse Stock Split	A reverse stock split, while technically neutral to market capitalization, is often perceived negatively by investors as it frequently indicates a company's struggle to maintain its stock price above exchange minimums. This can lead to reduced investor confidence, increased short-selling interest, a	Bearish	1-3m	0.80
2026-08-21	Gossamer Bio, Inc. Follow-On — $250M	Direct equity dilution, increased cash runway, reduced near-term bankruptcy risk, potential for increased R&D spend, and market perception of financing terms.	mixed	1-3m	0.80

Continue this research

Build your Gossamer Bio, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

Research Gossamer Bio, Inc. · $399/mo

This ledger is regenerated from Market Ontology's public event pipeline. View the GOSS entity page →

Gossamer Bio, Inc. (GOSS): the developments shaping its investment case

Research Gossamer Bio, Inc. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-09

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Bearish· 1-3m

2026-08-21

Gossamer Bio, Inc. Follow-On — $250M

Channel: Direct equity dilution, increased cash runway, reduced near-term bankruptcy risk, potential for increased R&D spend, and market perception of financing terms.

mixed· 1-3m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-08-21	multiple	Bearish	Incremental float typically compresses near-term multiple absent revenue acceleration.
2026-08-21	share_count	Bullish	Primary equity issuance increases diluted share count.
2026-07-01	interest_expense	Bullish	Coupon adds to interest expense until conversion.
2026-07-01	dilution	Bullish	Convertible issuance creates contingent dilution at conversion price.
2026-06-17	share_count	Bullish	Stock component of consideration dilutes existing acquirer holders.
2026-06-17	net_debt	Bullish	Cash component of consideration is typically debt-funded, raising net debt.
2026-06-17	revenue	Bullish	Acquisition adds target revenue to acquirer P&L on close.
2026-06-17	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-06-17	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.

Event impact log

2 events mapped to GOSS since 2026-08-21. Evidence through 2026-09-09.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-09	Gossamer Bio Announces 1-for-80 Reverse Stock Split	A reverse stock split, while technically neutral to market capitalization, is often perceived negatively by investors as it frequently indicates a company's struggle to maintain its stock price above exchange minimums. This can lead to reduced investor confidence, increased short-selling interest, a	Bearish	1-3m	0.80
2026-08-21	Gossamer Bio, Inc. Follow-On — $250M	Direct equity dilution, increased cash runway, reduced near-term bankruptcy risk, potential for increased R&D spend, and market perception of financing terms.	mixed	1-3m	0.80